secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2024-03-11T23:59:59+00:00
Accession:  0001193125-24-064310
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.02, 3.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon raises $250M via convertible preferred stock; Q4 net loss widens to $48.2M
--------------------------------------------------------------------------------

- Gross proceeds of ~$250M from 2.3M Series A Convertible Preferred shares at $108.50 each, convertible into 115.2M common shares upon stockholder approval of charter increase to 450M shares.
- Q4 2023 net loss $48.2M ($0.20 loss per share) vs $30.5M loss in Q4 2022; revenue of $0.7M from INPEFA commercialization.
- Full-year 2023 net loss $175.6M ($0.79 loss per share) vs $101.9M in 2022; SG&A increased to $114M, driven by INPEFA launch costs.
- Cash and investments $170.0M at Dec 31, 2023; private placement expected to close March 13, 2024.
- Pipeline: LX9211 Phase 2b PROGRESS study enrolling; Phase 3 prep for sotagliflozin in HCM and NDA resubmission for type 1 diabetes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000119312524064310/0001193125-24-064310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000119312524064310/d766707d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-064310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer